NCT05502523Recruiting
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
The Impact of Surgical Technique on Circulating Tumor DNA in Early-Stage Non-Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 1 Aug 2022
- Start date
- 31 Aug 2022
- Primary completion date
- 1 Jan 2027
- Lead sponsor
- Thomas Jefferson University
- Diseases
- Lung cancer
- NCT number
- NCT05502523
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 31 Aug 2022 to the primary completion date, 1 Jan 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Preoperative chemotherapy, immunotherapy, or radiation therapy
Other illness
- Previous cancer diagnosis within 5 years (except ductal carcinoma in situ \[DCIS\] of the breast, superficial bladder cancer, non-melanoma skin primary, other malignancy that does not require treatment).
Other
- Receipt of perioperative blood transfusion
Who the study is looking for
- Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC
- Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Abington Memorial Hospital Coordinator of this site? Confirm its status | Abington | United States | Recruiting |
| Jefferson Health Northeast Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
| Thomas Jefferson University Hospital Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
| Asplundh Cancer Pavilion at Jefferson Health Coordinator of this site? Confirm its status | Willow Grove | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.